January 1, 1995Thrombosis and Haemostasis
Low Molecular Weight Heparins (LMWH) in the Treatment of Patients with Acute Venous Thromboembolism
Why the study?
Does low molecular weight heparin reduce recurrent venous thromboembolism and major bleeding compared to unfractionated heparin in patients with acute venous thromboembolism?
Population
Patients with acute venous thromboembolism
Comparison
Low molecular weight heparin (LMWH) vs Unfractionated heparin
Design
Meta-analysis, Included double blind studies or those with blinded assessment…
Follow-up
first 15 days and over the entire period of anticoagulant…
Authors
Discussion
Loading...
Member takes
Implication
LMWH preferred over UFH for acute VTE; confirms superiority in reducing recurrence and bleeding from level 1 meta-analysis.
Structured PICO
Does low molecular weight heparin reduce recurrent venous thromboembolism and major bleeding compared to unfractionated heparin in patients with acute venous thromboembolism?
P
Population
Patients with acute venous thromboembolism
I
Intervention
Low molecular weight heparin (LMWH)
C
Comparator
Unfractionated heparin
O
Outcome
Symptomatic recurrent venous thromboembolism and major bleedinghard clinical
LMWH is superior to unfractionated heparin in reducing recurrent venous thromboembolism, major bleeding, and mortality in patients with acute venous thromboembolism.
Cite This Study
Hirsh et al. (1995) studied this question.